Protocol Ledger

NCT06841679 · Phase II/III · RECRUITING

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Interventional Phase II/III clinical trial protocol NCT06841679 sponsored by Beijing Biostar Pharmaceuticals Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-28 Enrollment: 778 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06841679
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)778 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06841679
Protocol FieldVerified Registry Value
NCT IdentifierNCT06841679
Consolidated Lead SponsorBeijing Biostar Pharmaceuticals Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment778 participants (ESTIMATED)
Registered Start Date2025-08-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI